Information Technology
Equasens: 2024 annual revenue
Villers-lès-Nancy, 6 February 2025 - 6:00 p.m. (CET)
PRESS RELEASE
2024 annual revenue: €216.8 million including €58.6 million in Q4 (+2.6% on a reported basis and -0.4% like-for-like)
unaudited
Note: Acquisitions in 2023 and 2024 (Atoopharm, Speach2Sense, Pratilog, ADV in Germany - now Pharmagest Germany) and Digipharmacie) have been restated in the scope of consolidation.
Maintaining a strategy of external growth, in December 2024 Equasens Group acquired 90% of the capital of Calimed SAS, a software publisher for private practitioners and surgeons (with no consolidated revenue in Q4 2024).
Equasens Group, (Euronext Paris™ - Compartment B - FR 0012882389 -EQS), a leading provider of digital solutions for healthcare professionals , reported full-year revenue for the 12-month period ending 31 December 2024 of €216.8m, contracting 1.4% on a reported basis. Like-for-like (organic growth), i.e. excluding the effects of acquisitions and the impact of the Ségur digital healthcare investment programme, revenue decreased by 3.7%.
No businesses were transferred between Divisions in FY 2024.
In Q4 2024 alone, Equasens Group registered sales of €58.6m, up 2.6% on a reported basis at 31 December 2023 (-0.4% like-for-like).
In Q4 2024, the Division grew 2.9% to €43.4m on a reported basis compared with Q4 2023, including €1.7m in restated sales linked to acquisitions in Q4 2023 and 2024. Like-for-like, the division's sales declined 1.1% in the last quarter.
This Division accounts for 75.4% of total revenue.
This Division accounts for 14.8% of total revenue.
This Division accounts for 5.2% of total revenue.
The Division accounts for 3.6% of total revenue.
The Division accounts for 1.0% of total revenue.
2025 outlook
Based on the encouraging indicators for Q4 2024, the Group is looking ahead to 2025 with confidence. Positive momentum is expected for the first half of the year, benefiting notably by a favourable base effect at the start of the year. A significant acceleration is expected in the second half with nominal growth of nearly 10%, driven by the capital expenditures and the roll-out of new solutions (software, hardware and services).
In this context, Equasens Group is in the process of implementing a major strategic transformation to SaaS (Software as a Service) business model. This transition entails the gradual migration from solutions hosted at healthcare professionals' premises to solutions hosted in the Group's data centers which are certified Health Data Hosting (HDS) and ISO 27001. The new add-on modules are now developed almost exclusively for SaaS solutions which will increase the proportion of recurring revenues. This transformation is driven by a robust cloud infrastructure and customised support to assist our customers with their digital transition.
At the same time, the Group is continuing to invest in Artificial Intelligence and accelerating its integration into its business tools to enhance its range of decision-making tools. This development brings real added value to healthcare professionals by making the prescription process more secure, providing personalised patient support and optimized time management.
Backed by a solid financial structure, the Group will continue to monitor potential opportunities for external growth.
This guidance does not take into account the potential effect of cyclical or macro-economic events that could have a direct or indirect impact on the healthcare sector.
Financial calendar:
About Group Equasens
Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1,300 people across Europe.
Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.
And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.
Listed on Euronext Paris™ - Compartment B
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC SMALL and CAC All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS
Get all the news about Equasens Group www.equasens.com and on LinkedIn
CONTACTS
EQUASENS Group
Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com
Financial communications agency:
FIN'EXTENSO - Isabelle Aprile
Tel.: +33 (0)6 17 38 61 78 - i.aprile@finextenso.fr
Forward-looking statements
This press release contains forward-looking statements that are not guarantees of future performance and are based on current opinions, forecasts and assumptions, including, but not limited to, assumptions about Equasens' current and future strategy and the environment in which Equasens operates. These involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to materially differ from those expressed in or implied by such forward-looking statements. These risks and uncertainties include those detailed in Chapter 3 "Risk factors" of the Universal Registration Document filed with the French financial market authority (Autorité des Marchés Financiers or AMF) on April 29, 2024 under number D.24-0366. These forward-looking statements are valid only as of the date of this press release.
1 An investment programme rolled out by the French government to support the national strategy for eHealth acceleration.
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti